S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
Top 10 Searched Stocks on MarketBeat All-Access
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
3 Dividend Kings With Royally Good Upside
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Southwest Airlines brings back dividend as travel rebounds
Could trawler cams help save world's dwindling fish stocks?
Minerals for Green Revolution a Massive Investor Opportunity (Ad)
Closing prices for crude oil, gold and other commodities
Why You Should Avoid Carvana Even if it Avoids Bankruptcy
NASDAQ:CLSN

Imunon - CLSN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
$1.95
▼
$2.63
52-Week Range
N/A
Volume
711 shs
Average Volume
150,471 shs
Market Capitalization
$13.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00
CLSN stock logo

About Imunon (NASDAQ:CLSN) Stock

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Stock News Headlines

October 3, 2022 | globenewswire.com
Imunon Reports Partial Results from Ongoing Non-human Primate Study - GlobeNewswire
October 3, 2022 | globenewswire.com
Imunon Appoints James E. Dentzer to its Board of Directors - GlobeNewswire
September 29, 2022 | globenewswire.com
Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) - GlobeNewswire
September 28, 2022 | globenewswire.com
IMUNON to Present at Chardan's 6th Annual Genetic Medicines - GlobeNewswire
September 19, 2022 | globenewswire.com
Celsion Corporation Announces Company Name Change to Imunon, Inc. - GlobeNewswire
September 19, 2022 | finance.yahoo.com
Celsion Corporation Announces Company Name Change to Imunon, Inc.
September 15, 2022 | globenewswire.com
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer - GlobeNewswire
September 15, 2022 | finance.yahoo.com
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
September 12, 2022 | benzinga.com
Celsion (NASDAQ:CLSN) – Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global I - Benzinga
September 12, 2022 | finance.yahoo.com
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
September 9, 2022 | benzinga.com
Celsion (NASDAQ:CLSN) – Celsion Earnings Perspective: Return On Capital Employed - Benzinga
September 9, 2022 | msn.com
Celsion Earnings Perspective: Return On Capital Employed
September 7, 2022 | benzinga.com
Celsionoration (CLSN) – Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investme - Benzinga
September 7, 2022 | globenewswire.com
Celsion Corporation to Present at the H.C. Wainwright 24th - GlobeNewswire
September 7, 2022 | finance.yahoo.com
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 5, 2022 | reuters.com
CLSN.OQ - Celsion Corporation | Stock Price & Latest News | Reuters
September 1, 2022 | globenewswire.com
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program - GlobeNewswire
September 1, 2022 | finance.yahoo.com
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
August 30, 2022 | finance.yahoo.com
CLSN: Complete Enrollment of OVATION 2 Study Expected in 3Q22…
August 15, 2022 | seekingalpha.com
Celsion GAAP EPS of -$0.87, revenue of $0.13M - Seeking Alpha
August 15, 2022 | benzinga.com
Recap: Celsion Q2 Earnings - Benzinga
August 15, 2022 | globenewswire.com
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update - GlobeNewswire
August 15, 2022 | finance.yahoo.com
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
August 14, 2022 | seekingalpha.com
Celsion Q2 2022 Earnings Preview
August 9, 2022 | globenewswire.com
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022 - GlobeNewswire
See More Headlines

Receive CLSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imunon and its competitors with MarketBeat's FREE daily newsletter.

CLSN Company Calendar

Last Earnings
8/15/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLSN
CUSIP
N/A
CIK
749647
Web
www.celsion.com
Phone
(609) 896-9100
Fax
609-896-2200
Employees
27
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$16.00
High Stock Price Forecast
$16.00
Low Stock Price Forecast
$16.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-20,770,000.00
Net Margins
-5,229.80%
Pretax Margin
-5,506.60%
Return on Equity
-50.18%
Return on Assets
-36.94%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
6.52
Quick Ratio
6.52

Sales & Book Value

Annual Sales
$500,000.00
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.66 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
7,099,000
Free Float
6,768,000
Market Cap
$13.91 million
Optionable
Optionable
Beta
2.27

Social Links


Key Executives

  • Mr. Michael H. Tardugno (Age 71)
    Exec. Chairman
    Comp: $1.01M
  • Mr. Jeffrey W. Church CPA (Age 65)
    CPA, CFO, Exec. VP & Corp. Sec.
    Comp: $528.54k
  • Dr. Khursheed Anwer M.B.A. (Age 62)
    Ph.D., Exec. VP & Chief Scientific Officer
    Comp: $511.92k
  • Dr. Nicholas Borys (Age 63)
    Exec. VP & Chief Medical Officer
    Comp: $586.54k
  • Dr. Corinne Le Goff M.B.A.
    Pharm.D., CEO, Pres & Director
  • Mr. Timothy J. Tumminello (Age 64)
    Chief Accounting Officer & Controller
  • Ms. Marianne M. Lambertson
    VP of Communications & Investor Relations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













CLSN Stock - Frequently Asked Questions

Should I buy or sell Imunon stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Imunon in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLSN shares.
View CLSN analyst ratings or view top-rated stocks.

What is Imunon's stock price forecast for 2023?

1 brokers have issued twelve-month price targets for Imunon's stock. Their CLSN share price forecasts range from $16.00 to $16.00. On average, they expect the company's share price to reach $16.00 in the next year.
View analysts price targets for CLSN or view top-rated stocks among Wall Street analysts.

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:CLSN) posted its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.87) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.25. Imunon had a negative net margin of 5,229.80% and a negative trailing twelve-month return on equity of 50.18%. During the same period in the previous year, the business earned ($0.90) EPS.

When did Imunon's stock split?

Shares of Imunon reverse split on the morning of Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Imunon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Imunon investors own include Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), Novan (NOVN), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS), Agenus (AGEN) and CBL & Associates Properties (CBL).

What is Imunon's stock symbol?

Imunon trades on the NASDAQ under the ticker symbol "CLSN."

How much money does Imunon make?

Imunon (NASDAQ:CLSN) has a market capitalization of $0.00 and generates $500,000.00 in revenue each year.

How can I contact Imunon?

Imunon's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The official website for the company is www.celsion.com. The biotechnology company can be reached via phone at (609) 896-9100, via email at jchurch@celsion.com, or via fax at 609-896-2200.

This page (NASDAQ:CLSN) was last updated on 12/8/2022 by MarketBeat.com Staff